Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.
Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.
复制标题
DOI：
10.4049/jimmunol.155.11.5323
复制
发表时间：
1995-12
影响因子：
4.4
通讯作者：
L. Ramarathinam;S. Sarma;M. Marić;Min Zhao;Guchen Yang;Lieping Chen;Yang Liu
中科院分区：
文献类型：
--
作者：
L. Ramarathinam;S. Sarma;M. Marić;Min Zhao;Guchen Yang;Lieping Chen;Yang Liu
不同谱系的肿瘤是否共享共同的Ag是理解抗肿瘤免疫应答和设计Ag特异性肿瘤免疫治疗的关键问题。由于个体来源的肿瘤之间缺乏交叉保护，已经提出肿瘤Ag对个体肿瘤具有特异性。在这里，我们表明缺乏交叉保护不是由于缺乏共享的肿瘤抗原。因此，用共刺激分子B7转染的浆细胞瘤J558在体内激活交叉反应性CTL应答。交叉反应性CTL识别的主要抗原是P1A，其在肥大细胞瘤P815、浆细胞瘤J558和纤维肉瘤Meth A中表达。令人惊讶的是，在用表达P1A或转染B7的P815细胞免疫后，在表达P1A的肿瘤中没有检测到显著的交叉保护。我们的研究结果表明，多个谱系的肿瘤没有交叉保护，即使他们共享一个肿瘤抗原，可以识别的CTL。这些结果对肿瘤免疫治疗具有重要意义。
Whether tumors of different lineages share common Ags is a critical issue for understanding anti-tumor immune responses and for designing Ag-specific tumor immunotherapy. Because of lack of cross-protection among individually derived tumors, it has been proposed that tumor Ags are specific for individual tumors. Here we show that lack of cross-protection is not due to lack of a shared tumor Ag. Thus, a plasmocytoma J558 transfected with the costimulatory molecule B7 activates a cross-reactive CTL response in vivo. The major Ag recognized by the cross-reactive CTL is P1A, which is expressed in mastocytoma P815, plasmocytoma J558, and fibrosarcoma Meth A. Surprisingly, no significant cross-protection can be detected among P1A-expressing tumors after immunization with either P1A-expressing or B7-transfected P815 cells. Our results demonstrate that multiple lineages of tumors are not cross-protected even though they share a tumor Ag that can be recognized by CTL. These results have important implications for tumor immunotherapy.